Recently, a new NMDA receptor blocker, RL-208, has been tested on a mouse model of late-onset AD, showing cognitive function improvement in terms of increased synaptic protein density, increased phosphorylation of NMDA2B, reduced protein-related apoptosis, as well as decreased phosphorylated tau levels [114]. Here, MAPT is linked to Alzheimer disease.